Gilead Sciences, Inc.: Kite's CAR T-cell Therapy Tecartus Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
-- Approval Marks Kite's Fourth Indication in Europe for its Two Cell Therapies and First in Leukemia -- -- Overall Complete Remission of 71% and a Median Overall Survival of More Than Two Years
Source: finanznachrichten.de